Boston Biotech Verve Tests ‘CRISPR 2.0′ in a Patient for the First Time

“Scientists are rewriting the code of life with a new technology that promises to cure inherited diseases by precisely correcting genetic typos. Known as base editing, the technology empowers researchers to pick a single letter amongst the three billion that compose the human genome, erase it, and write a new letter in its place.”

We’ve made the jump from gene editing of plants and animals to humans…it is here.

https://www.msn.com/en-us/health/medical/boston-biotech-verve-tests-e2-80-98crispr-20-e2-80-b2-in-a-patient-for-the-first-time/ar-AAZtVsJ

Published by markskidmore

Mark Skidmore is Professor of Economics at Michigan State University where he holds the Morris Chair in State and Local Government Finance and Policy. His research focuses on topics in public finance, regional economics, and the economics of natural disasters. Mark created the Lighthouse Economics website and blog to share economic research and information relevant for navigating tumultuous times.

Leave a Reply

Discover more from Lighthouse Economics

Subscribe now to keep reading and get access to the full archive.

Continue reading